Navigation Links
Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
Date:9/4/2007

MIAMI LAKES, Fla., Sept. 4 /PRNewswire/ -- In an extensive analysis of clinical trials known as a meta-analysis, the CYPHER(R) Sirolimus-eluting Coronary Stent was associated with significantly lower risks of blood clots and the need for reintervention compared to the Taxus Stent out to 30 months after an angioplasty procedure. This meta-analysis of 16 randomized clinical trials and 8,695 patients, the largest analysis of its kind to date, is now posted on the Journal of the American College of Cardiology website and is expected in print later in the year.

"Over the past year, concerns have been raised regarding the long-term safety of all drug-eluting stents," said Professor Albert Schomig, M.D., from Deutsches Herzzentrum, Technische Universitat in Munich, Germany, one of the authors of the study. "In this meta-analysis of randomized controlled trials, the CYPHER(R) Stent was associated with a significant reduction in the risks of stent thrombosis and reintervention compared to the Taxus Stent. This reinforces the notion that there are marked differences between the CYPHER(R) Stent and the Taxus Stent and that the safety of these drug-eluting stents must be assessed separately."

Professor Schomig added, "We find these data compelling because they are consistent with other documented meta-analyses and reflect data from all of the randomized clinical trials directly comparing these drug-eluting stents. Meta-analyses like this are an important and well-accepted statistical method among clinicians worldwide for documenting similarities and differences between two treatment modalities. We understand and appreciate that such studies are open to various interpretations by researchers and clinicians."

The primary safety endpoint of the meta-analysis was protocol-defined stent thrombosis while the secondary safety endpoints were death and heart attack (myocardial infarction or MI). The primary efficacy endpoint was the need for reintervention (targ
'/>"/>

SOURCE Cordis Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
2. Largest National U.S. Healthcare Facility MRSA Study Reveals Infection Rates Eight Times Greater Than Previous Estimates
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
5. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... Research and Markets ( ... "North American Active Wound Care Market by ... & Ulcer), by End-User (In-Patient, & Out-Paient) - ... their offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,The North ... grow at a CAGR of 3.1% from 2014 ...
(Date:5/21/2015)... Calif. , May 21, 2015  Cardica, Inc. (Nasdaq: ... new employee Greg Watson , the company,s vice president ... of the company,s common stock, at a per share exercise ... 2015. The stock option was granted pursuant to Cardica, Inc.,s ... directors in May 2015 under Rule 5653(c)(4) of the Nasdaq ...
(Date:5/21/2015)... England , May 21, 2015 ... Bekämpfung von Arzneimittelfälschungen - Zwecks Leistungsvergleich ... Arzneimittelprüfdienstes wird auf EG-Mitgliedstaaten verwiesen, in ... betrieben werden.  Wählen Sie ein Aegate-Land: ... der Richtlinie zur Bekämpfung von Arzneimittelfälschungen ...
Breaking Medicine Technology:North American Active Wound Care Market 2015-2019 with Smith and Nephew, Molyncke HealthCare & ConvaTec Dominating 2Cardica Announces New Employment Inducement Grant 2EU-Arzneimittel-Richtlinie für gefälschte Medikamente; Aegate-Zusammenfassung als reale Bewertung aus Belgien 2EU-Arzneimittel-Richtlinie für gefälschte Medikamente; Aegate-Zusammenfassung als reale Bewertung aus Belgien 3
... Corporate Affairs – also called Public Affairs ... key success drivers for organizations. In many organizations, ... Government Affairs, Corporate Communications and Patient Advocacy – ... interactions with important external and internal partners. ...
... Nov. 5, 2010 Will power wheelchairs continue ... of federal regulatory and policy changes? There are ... providers in Nevada that the changes in Medicare policies may ... and services to beneficiaries. One of the ...
Cached Medicine Technology:Corporate Affairs Role in Internal and External Relationships Key to Organizational Success 2Medicare Policy Changes Will Make it More Difficult for Nevada Beneficiaries to Obtain Power Wheelchairs 2Medicare Policy Changes Will Make it More Difficult for Nevada Beneficiaries to Obtain Power Wheelchairs 3Medicare Policy Changes Will Make it More Difficult for Nevada Beneficiaries to Obtain Power Wheelchairs 4
(Date:5/22/2015)... 22, 2015 Gateway Building Concepts is ... The services the company specialize in include decks, additions, ... pool houses and much more. , The redesigned ... owner of the company. It includes two geometrical lines ... was thought out to be used with many things ...
(Date:5/22/2015)... A Phase 3 French study, ... of Clinical Oncology (ASCO)’s annual meeting at the ... those patients who received bevacizumab in addition to ... (Avastin® Genentech, Inc.) is an antibody that blocks ... routinely used to treat many other cancers, including ...
(Date:5/22/2015)... New York, NY (PRWEB) May 22, 2015 ... Bay Lightning vs. New York Rangers NHL Eastern Conference Finals ... finals is together unless specified otherwise in the ticket listing. ... New York Rangers are at the top of the Eastern ... League has had its share of ups and downs over ...
(Date:5/22/2015)... (PRWEB) May 22, 2015 In April ... In the past 9 years they have concentrated their ... United States and Canada. Because of this growth and ... established corporate offices in Denver, Colorado, Cleveland, Ohio, Houston, ... specializes in opening new dental offices, dental start ups, ...
(Date:5/22/2015)... Bryce Henson, local fitness icon and owner of ... accepted his program’s 100th client. Henson says that reaching ... location evidences the powerful impact his boot camp is ... Camp is the nation’s most popular and fastest growing ... across North America, Europe and Australia. Anaheim Fit Body ...
Breaking Medicine News(10 mins):Health News:Mesothelioma Research Organization Excited About Imminent Improvement to Standard of Care 2Health News:Cheap Lightning vs Rangers NHL Eastern Conference Finals Tickets: Ticket Down Slashes Ticket Prices on New York Rangers vs Tampa Bay Lightning Eastern Conference Playoffs 2Health News:Cheap Lightning vs Rangers NHL Eastern Conference Finals Tickets: Ticket Down Slashes Ticket Prices on New York Rangers vs Tampa Bay Lightning Eastern Conference Playoffs 3Health News:Healthy Living Brought to Anaheim— New Fitness Boot Camp Acquires 100 Clients 2
... of Health has announced that the Salk Institute will receive ... research center intended to accelerate brain research that lays the ... and neurological diseases. The new center is one of ... Neurological Disorders and Stroke to focus on basic brain research. ...
... N.Y., CAMBRIDGE, M.A. and SHENZHEN, CHINA (October 13, 2011) ... advocacy organization, and BGI, the largest genomic organization in ... sequencing, jointly announce their partnership to create the world,s ... spectrum disorders (ASD). Using the Autism Speaks Autism Genetic ...
... their own previous world-best efforts to pluck out just the ... core of multiple sclerosis and a large number of rare, ... directed stem cells from the human brain to become oligodendrocytes ... crucial fatty material that coats neurons and allows them to ...
... -- Women throughout the world will benefit from a ... aims to change the way in which ovarian cancer ... Partnership Against Cancer are providing a total of $5-million ... Program called COEUR. The program will identify new biomarkers ...
... (HealthDay News) -- The percentage of children with asthma in ... nearly doubled since the late 1990s, a new federal government ... Expenditure Panel Survey showed that the use of controller drugs ... 58 percent in 2007-2008, according to the latest News ...
... disparities between Latinos and non-Latino whites, mostly from a policy ... perspective of the patient, in terms of access, use and ... how do the physicians feel about the quality of care ... patients, compared with physicians whose patients are primarily white and ...
Cached Medicine News:Health News:Salk to accelerate brain research with $4.5 million NIH grant 2Health News:Autism Speaks and BGI to complete whole genome sequencing on 10,000 with autism 2Health News:Precision with stem cells a step forward for treating MS, other diseases 2Health News:Precision with stem cells a step forward for treating MS, other diseases 3Health News:Terry Fox Research Institute aims to change diagnosis and management of ovarian cancer worldwide 2Health News:Terry Fox Research Institute aims to change diagnosis and management of ovarian cancer worldwide 3Health News:Use of Asthma Controller Meds on the Rise Among U.S. Kids 2Health News:Physicians treating Latinos have high hurdles to jump, study shows 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: